Beschreibung

Dear Colleagues,

we are pleased to inform you that the MPN&MPNr-EuroNet meeting will be held in St.Gallen, Switzerland on May 14-16, 2025.

Scientific Meeting Organizers:

Tata Nageswara Rao, Christoph Driessen and Thomas Lehmann

Network of Experts on the Molecular Diagnosis of Myeloproliferative Neoplasm (MPN) and MPN-related congenital diseases (MPNr):

The MPN&MPNr-EuroNET network was established in 2009 to bring together scientists and physicians active in the fields of myeloprolifeative neoplasms (MPN) and related hereditary diseases (MPNr: hereditary erythrocytosis and thrombocytosis) to discuss advances and challenges in the biology and treatment options for myeloid neoplasms. Since its establishment, the MPN&MPNr-EuroNET network has been active in organizing meetings and fostering collaborations within and outside the network. Following the success of the 16th MPN&MPNr-EuroNet meeting in Belgrade in 2023, the 17th MPN&MPNr-EuroNET conference will take place on 14-16^th May 2025 in St. Gallen, Switzerland.

Ziele

Myeloproliferative neoplasms (such as PV, ET and myelofibrosis), hereditary erythrocytosis and thrombocytosis and mastocytosis are closely related clonal neoplasms of blood stem cells and are caused by genetic lesions leading to the uncontrolled production of certain myeloid lineages in affected individuals. In MPNs, the underlying genetic drivers are well catalogued, with mutations affecting JAK2 (JAK2-V617F or exon 12), Calreticulin (CALR-del52 or insertion 5), or the thrombopoietin receptor MPL (MPL-W515L). The discovery of JAK2-V617F mutation in the majority of patients with MPNs revolutionized the understanding of the pathomechanisms of the disease and also paved the way for the development of pharmacological inhibitors targeting JAK2. In the recent years, thanks to the improvements in single cell technologies, transgenics and next generation sequencing, significant advances have been made in the understanding of cellular and molecular mechanisms driving these clonal disorders. However, current therapies are not curative highlighting the need for unraveling pathomechanisms in further datils to discover novel curative treatment approaches.

The main goal of this international conference is to gather scientists and clinicians investigating and treating these devastatingl neoplasms to discuss advances, current challenges and future directions in myeloid neoplasms’ research, diagnostic and therapeutic approaches. This conference will provide an interactive and dynamic atmosphere and fosters the establishment of fruitful collaborations. This meeting highlights and celebrates the ’20-years of JAK2-V617F discovery’ with pioneers in the field as keynote speakers. In contrast to the past meetings, which were held mostly for two days, the 17th MPN&MPNr-EuroNET conference will take place in 3 days. As a new entity of the network, it also covers the biology and therapeutics of mastocytosis.

Key sessions and scientific topics:

• Pathomechanisms of myeloproliferative neoplasms - what is new?: Molecular pathogenesis, MPN clonal evolution; 20 Years of JAK2-V617F discovery: JAK inhibitors and beyond

• Novel diagnostic and therapeutic approaches and challenges in the management of MPNs

• Erythrocytosis (sporadic and familial) - from genetics to therapies

• Mastocytosis - biology and current therapies

Target audience:

• Fundamental, translational and clinical researchers studying blood malignancies

• Young researchers (PhD students, Post-docs and clinical residents)

• MPN, erythrocytosis and mastocytosis Patients

• Pharmaceutical companies and clinical research organizations and foundations

The program will include:

• 6 keynote lectures by renowned speakers

• 42 presentations by invited speakers

• Satellite symposium ’20-years of JAK2-V617F discovery’-JAK inhibitors and beyond

• Brief oral communications by young researchers

• Poster sessions

Learning objectives:

• 1. To share and discuss recent discoveries on the cellular and molecular pathogenesis of MPNs, erythrocytosis and mastocytosis

• 2. To gain new insights on recent advancements and criterias in treatment recommendations for MPN and mastocytosis patients including the emerging landscape of approved therapies

• 3. To gain updates on ongoing clinical trials investigating novel therapeutic agents for MPN, erythrocytosis and mastocytosis treatments.

This interactive and educational conference has been approved for SGH